HRT FINANCIAL LP Offloads Profusa Shares Just Before Reverse‑Split Vote, Fueling Insider Frenzy

HRT FINANCIAL LP’s Recent Sell‑Off Amid a Surge of Insider Activity

HRT FINANCIAL LP liquidated 18,395 shares of Profusa Inc. on August 17, 2026, at roughly $5.94 per share. The transaction cleared the owner’s position to zero, following a prior sale of 3,163 shares on August 14 at $0.90 that brought the holdings to 71,035 shares. The timing—just weeks before Profusa’s special shareholder meeting on September 18 to discuss a reverse‑stock‑split—suggests the firm may be capitalizing on the anticipated price compression that typically accompanies such a restructuring.

Implications for Investors and Company Outlook

The sell‑off comes at a critical juncture. A reverse‑stock‑split could consolidate Profusa’s diluted equity base and potentially lift the share price, but it also signals that insiders are wary of the company’s current valuation. For investors, the move may be interpreted in two ways: a cautious bet that the split will create upside, or a warning that the company’s prospects are uncertain. Those holding Profusa stock should watch for post‑split liquidity and any shifts in the board’s strategic direction, especially given the upcoming vote on an adjournment proposal that could delay future capital‑raising efforts.

HRT FINANCIAL LP: A Pattern of Opportunistic Selling

Historically, HRT FINANCIAL LP has maintained a low‑profile, opportunistic trading style. In its 2026‑08‑14 filing, the firm sold 3,163 shares at $0.90, a stark contrast to the $5.94 price paid on August 17. The firm’s ownership level fluctuated but never exceeded 71,035 shares, indicating a strategy of maintaining a manageable stake while extracting value when market conditions shift. Compared to other insiders—such as CFO Fred Knechtel, who bought 818,961 shares earlier in the year—HRT’s actions underscore a divergent view on Profusa’s trajectory.

A Broader Insider Landscape

The insider activity snapshot shows a mix of purchases and sales across the board. While some executives, like Knechtel, have increased exposure, others—most notably NorthView Sponsor I, LLC—have sold millions of shares, hinting at broader uncertainty about the company’s future. HRT’s recent sale, positioned amid these broader moves, could be a bellwether for the sentiment among institutional stakeholders.

What This Means Going Forward

For the next few weeks, market participants should focus on the outcomes of the September 18 meeting. A successful reverse‑stock‑split could restore confidence and potentially reverse the selling trend. Conversely, a failed or delayed vote might reinforce the notion that Profusa’s valuation is too low to sustain its Nasdaq listing without significant capital infusion. Investors would do well to monitor HRT’s subsequent filings; if the firm remains liquidated, it may signal a strategic pivot away from Profusa altogether.